Younger patients with high-risk diffuse large B-cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOEP+I) in patients aged 18-60 years with DLBCL and age-adjusted internat...
E. Shumilov, M. Ziepert, B. Friedrichs et al.· British Journal of Haematolo...· 0 citations
For patients with large B-cell lymphoma progressing after multiple lines of therapy few treatment options remain, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers...
Evgenii Shumilov, Lina J. Kolloch, Philipp Faustmann et al.· Blood Advances· 0 citations
The data support recent recommendations advising treating patients with tandem transplantation regimes and support the idea that the optimal consolidation strategy remains to be defined.
Maria Dampmann, S. Flossdorf, Julius Keyl et al.· European Journal of Haematol...· 0 citations
BACKGROUND
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy for relapsed/refractory (r/r) large B-cell lymphoma (LBCL), whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a potential salvage option. Comparative real-world data between bot...
M. Maulhardt, Lina J. Kolloch, Gina Westhofen et al.· Clinical Lymphoma, Myeloma &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
